866-997-4948(US-Canada Toll Free)

Rectal Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Jul 2013

Category :

Cancer

No. of Pages : 65 Pages


Global Markets Directs, Rectal Cancer - Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rectal Cancer. Rectal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Rectal Cancer.
  • A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Rectal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Rectal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Rectal Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Rectal Cancer 7
Rectal Cancer Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Rectal Cancer Therapeutics Products under Development by Companies 13
Rectal Cancer Therapeutics Products under Investigation by Universities/Institutes 14
Companies Involved in Rectal Cancer Therapeutics Development 15
Eli Lilly and Company 15
GenVec, Inc. 16
Merck & Co., Inc. 17
Merck KGaA 18
Peregrine Pharmaceuticals, Inc. 19
Synta Pharmaceuticals Corp. 20
Nanobiotix 21
Isofol Medical AB 22
Rectal Cancer Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
cixutumumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
emepepimut-S - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
TNFerade - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ganetespib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
bavituximab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
veliparib - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
dalotuzumab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
NBTX-IV - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Rectal Cancer Therapeutics Drug Profile Updates 49
Rectal Cancer Therapeutics - Dormant Products 61
Rectal Cancer Product Development Milestones 62
Featured News & Press Releases 62
Nov 03, 2012: Merck KGaA Ceases Supply Of Cancer Drug Erbitux To Greek Hospitals 62
Sep 06, 2012: NCCN Oncology Research Program Receives Funding From GSK To Evaluate Clinical Effectiveness Of Trametinib 62
Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy 63

Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Table


Number of Products Under Development for Rectal Cancer, H2 2013 7
Products under Development for Rectal Cancer Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Clinical Stage Development, H2 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Eli Lilly and Company, H2 2013 15
GenVec, Inc., H2 2013 16
Merck & Co., Inc., H2 2013 17
Merck KGaA, H2 2013 18
Peregrine Pharmaceuticals, Inc., H2 2013 19
Synta Pharmaceuticals Corp., H2 2013 20
Nanobiotix, H2 2013 21
Assessment by Monotherapy Products, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 27
Rectal Cancer Therapeutics Drug Profile Updates 49
Rectal Cancer Therapeutics Dormant Products 61

List of Chart


Number of Products under Development for Rectal Cancer, H2 2013 7
Products under Development for Rectal Cancer Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Early Clinical Stage Products, H2 2013 11
Pre-Clinical Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 23
Assessment by Route of Administration, H2 2013 24
Assessment by Stage and Route of Administration, H2 2013 25
Assessment by Molecule Type, H2 2013 26
Assessment by Stage and Molecule Type, H2 2013 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *